Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Meta-Regression of Herpes Zoster Incidence Worldwide.
Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, Yawn BP. Curran D, et al. Among authors: callegaro a. Infect Dis Ther. 2022 Feb;11(1):389-403. doi: 10.1007/s40121-021-00567-8. Epub 2021 Dec 7. Infect Dis Ther. 2022. PMID: 34874546 Free PMC article.
Burden-of-illness vaccine efficacy.
Callegaro A, Curran D, Matthews S. Callegaro A, et al. Pharm Stat. 2020 Sep;19(5):636-645. doi: 10.1002/pst.2020. Epub 2020 Mar 27. Pharm Stat. 2020. PMID: 32220002 Free PMC article.
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of Protection.
Danier J, Callegaro A, Soni J, Carmona A, Kosalaraska P, Rivera L, Friel D, Pu W, Vantomme V, Dbaibo G, Innis BL, Schuind A, Zaman K, Wilson J. Danier J, et al. Among authors: callegaro a. Open Forum Infect Dis. 2021 Sep 25;9(2):ofab477. doi: 10.1093/ofid/ofab477. eCollection 2022 Feb. Open Forum Infect Dis. 2021. PMID: 35083365 Free PMC article.
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. Curigliano G, et al. Among authors: callegaro a. Breast Cancer Res Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14. Breast Cancer Res Treat. 2016. PMID: 26975189 Clinical Trial.
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. Limentani SA, et al. Among authors: callegaro a. Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18. Breast Cancer Res Treat. 2016. PMID: 26993131 Clinical Trial.
Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.
Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, Janssens M, Leroux-Roels G, Marchant A, van den Berg RA, Garçon N, van der Most R, Didierlaurent AM; ECR-002 Study Group. Burny W, et al. Among authors: callegaro a. Front Immunol. 2017 Aug 14;8:943. doi: 10.3389/fimmu.2017.00943. eCollection 2017. Front Immunol. 2017. PMID: 28855902 Free PMC article.
142 results